EverSource Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

EverSource Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.9K	Buy	108 +33	+44%	+$8.78K	﹤0.01%	2281
2025 Q4	$18.5K	Buy	75 +12	+19%	+$2.53K	﹤0.01%	2436
2025 Q3	$11.1K	Buy	63 +32	+103%	+$4.79K	﹤0.01%	2765
2025 Q2	$4.26K	Sell	31 -24	-44%	-$3.52K	﹤0.01%	3227
2025 Q1	$9.92K	Buy	55 +32	+139%	+$5.38K	﹤0.01%	2113
2024 Q4	$3.6K	Sell	23 -6	-21%	-$1.06K	﹤0.01%	2486
2024 Q3	$5.28K	Sell	29 -6	-17%	-$1.16K	﹤0.01%	2206
2024 Q2	$7.3K	Buy	35 +21	+150%	+$3.53K	﹤0.01%	2039
2024 Q1	$2.14K	Buy	+14	New	+$1.95K	﹤0.01%	2359

Other funds holding KRYS

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return